Claro Advisors LLC Expands Its Investment in Intuitive Surgical, Inc.

Claro Advisors LLC has increased its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by an impressive 54.8% during the third quarter, according to their recent filing with the Securities and Exchange Commission (SEC). By the end of the quarter, they owned a total of 1,398 shares, having added 495 shares to their portfolio. The market value of Claro Advisors LLC’s stake in Intuitive Surgical reached approximately $687,000.

Other institutional investors have also made adjustments to their stakes in Intuitive Surgical. Ullmann Wealth Partners Group LLC raised its holding by 1.6%, now owning 1,329 shares worth $653,000 after purchasing an additional 21 shares. One Wealth Management Investment & Advisory Services LLC grew its position by 3.4%, resulting in 697 shares valued at $310,000 after acquiring 23 more. Daymark Wealth Partners LLC increased its stake by 0.3%, totaling 7,027 shares worth $3,452,000 after buying 24 shares. Meanwhile, Indiana Trust & Investment Management CO boosted its stake by 5.3%, with 500 shares now valued at $222,000 following a purchase of 25 shares. Hoxton Planning & Management LLC also raised its position by 4.9%, owning 534 shares worth $238,000 after acquiring 25 additional shares. Overall, institutional investors and hedge funds collectively own 83.64% of Intuitive Surgical’s stock.

Insider Trading Activities

In related news, insider Mark Brosius sold 2,115 shares on September 12th at an average price of $491.91, totaling $1,040,389.65 from the sale. After this transaction, Brosius retained 295 shares, valued at about $145,113.45, which constituted a minor decrease in his ownership. This transaction was disclosed to the SEC. Additionally, EVP Robert Desantis sold 1,413 shares on July 26th, with an average sale price of $438.60, amounting to $619,741.80. After this sale, he was left with 5,506 shares valued at $2,414,931.60, marking a similar slight decrease in his position. Over the past three months, insiders have sold a total of 53,120 shares worth approximately $25,528,753. Company insiders hold about 0.90% of the total stock.

Stock Performance of Intuitive Surgical

As of Friday, Intuitive Surgical stock opened at $521.15. Throughout the year, the stock reached a low of $254.85 and a high of $523.34. The company’s 50-day moving average is currently $483.85, while the 200-day moving average stands at $438.17. Intuitive Surgical has a market capitalization of $184.85 billion, a P/E ratio of 94.07, a P/E/G ratio of 5.40, and a beta of 1.39.

The last quarterly earnings report released on July 18th showed earnings per share of $1.78, exceeding analysts’ expectations of $1.54 by $0.24. The company’s return on equity was recorded at 13.04%, with a net margin of 27.65%. Revenue for the quarter was $2.01 billion, surpassing the expected $1.97 billion. Compared to the same quarter last year, revenue increased by 14.5%, highlighting strong growth. Analysts forecast that Intuitive Surgical, Inc. will achieve $5.22 earnings per share for the current financial year.

Changes in Analyst Ratings

Recently, several brokerage firms have provided updates on ISRG shares. Truist Financial has raised its price target from $520.00 to $570.00 and assigned a “buy” rating. The Goldman Sachs Group has set a price target of $604.00, while Raymond James increased its target from $500.00 to $540.00, maintaining an “outperform” rating. Leerink Partners has also adjusted its projections, setting a new price objective of $502.00. Furthermore, Royal Bank of Canada increased its target from $525.00 to $555.00. Among analysts, one has rated the stock as a sell, five as hold, and fourteen as buy, contributing to an overall average rating of “Moderate Buy” and a consensus price target of $513.74.

Overview of Intuitive Surgical

Intuitive Surgical, Inc. specializes in the development, manufacturing, and marketing of medical products designed to enhance minimally invasive care for physicians and healthcare providers. They are well known for their da Vinci Surgical System, which enables complex surgeries through a minimally invasive approach, along with the Ion endoluminal system that broadens their offerings into diagnostic procedures, allowing for minimally invasive lung biopsies.

Investment, Shares, Stock